Roche CEO cautious on Alzheimer’s trial despite Eisai’s success
Last month’s breakthrough Alzheimer’s discovery from Eisai and Biogen doesn’t mean that Roche will also succeed, says CEO Severin Schwan – while analysts aren’t expecting success at all.
By Naomi Kresge, bloomberg
Groundbreaking results in Alzheimer’s disease last month don’t necessarily mean that Roche Holding AG will be able to deliver similar success in its own upcoming clinical trial, Chief Executive Officer Severin Schwan cautioned.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Alzheimer’s progression slowed by drug in major trial
For subscribers
